Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | RXRA | P19793 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | CCKAR | P32238 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL5056806 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL29380299 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL31002987 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147655 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL556763 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL6251405 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41503 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41502 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41663 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147661 | 0.99 | CYP2C9 (0.98) | CYP2C9KDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4933165-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-06-12 | — | — | US | claimed |
| US-4929437-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-05-29 | — | — | US | claimed |
| US-9168141-B2 | Medical prosthetic devices and implants having improved biocompatibility | ASTRA TECH AB (SE) | 2015-10-27 | — | — | US | disclosed |
| US-20130102635-A1 | Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal | AEGERION PHARMACEUTICALS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20120130491-A1 | MEDICAL PROSTHETIC DEVICES HAVING IMPROVED BIOCOMPATIBILITY | STRAUMANN HOLDING AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20110124819-A1 | MODIFIED HALOGENATED POLYMER SURFACES | BASF SE (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20100226886-A1 | Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C | AEGERION PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20080269910-A1 | Medical prosthetic devices having improved biocompatibility | STRAUMANN HOLDING AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080253985-A1 | Compositions for Lowering Serum Cholesterol and/or Triglycerides | AEGERION PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1492579-B1 | MEDICAL PROSTHETIC DEVICES HAVING IMPROVED BIOCOMPATIBILITY | NUMAT AS (NO) | 2008-09-10 | — | — | EP | disclosed |
| US-7410502-B2 | Medical prosthetic devices having improved biocompatibility | NUMAT AS (NO) | 2008-08-12 | — | — | US | disclosed |
| EP-1339437-B1 | MEDICAL PROSTHETIC DEVICES AND IMPLANTS COATED WITH METAL HYDRIDES AND BIOMOLECULES HAVING IMPROVED BIOCOMPATIBILITY | ASTRA TECH AB (SE) | 2004-07-28 | — | — | EP | disclosed |
| US-20040083006-A1 | Medical prosthetic devices having improved biocompatibility | ASTRA TECH AB (NO) | 2004-04-29 | — | — | US | disclosed |
| WO-2003086495-A1 | MEDICAL PROSTHETIC DEVICES HAVING IMPROVED BIOCOMPATIBILITY | ASTRA TECH AB (SE) | 2003-10-23 | — | — | WO | disclosed |
| EP-1339437-A1 | MEDICAL PROSTHETIC DEVICES AND IMPLANTS HAVING IMPROVED BIOCOMPATIBILITY | Astra Tech AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| US-20020111694-A1 | Medical prosthetic devices and implants having improved biocompatibility | BIOTI AS (NO) | 2002-08-15 | — | — | US | disclosed |
| WO-2002045764-A1 | MEDICAL PROSTHETIC DEVICES AND IMPLANTS HAVING IMPROVED BIOCOMPATIBILITY | ASTRA TECH AB (SE) | 2002-06-13 | — | — | WO | disclosed |
| EP-0383432-B1 | COENZYME Q10 WITH HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0383432-A1 | Coenzyme Q10 with HMG-COA reductase inhibitors | MERCK & CO. INC. (US) | 1990-08-22 | — | — | EP | disclosed |
| US-4933165-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226886-A1 | Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C | CETP, MTTP, LIPC | HMGCR 9/4885CYP2C9 287/4885KDM4E 4125/4885 |
| US-20130102635-A1 | Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal | HMGCR, MTTP, CETP | HMGCR 1/4885CYP2C9 398/4885KDM4E 2835/4885 |
| US-20080253985-A1 | Compositions for Lowering Serum Cholesterol and/or Triglycerides | CETP, LCAT, HMGCR | HMGCR 3/4885CYP2C9 546/4885KDM4E 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.